CABS
Chinese American Biopharmaceutical Society
北美华人生物医药协会

Pursuing Science for Cure

CABS BioPacific Conference 2019

2019 BioPacific Conference
21th Annual Conference of CABS

8:00AM - 7:00PM, June 22, 2019

San Mateo Marriott, 1770 South Amphlett Blvd., San Mateo, CA 94402

Pursuing Science for Cure

BIOPACIFIC CONFERENCE 2019 SPONSORS

Long-term Partners and Sponsors

KENSON VENTURES LLC

HANHAI Silicon Valley 瀚海硅谷中心

Diamond Sponsors

Acro BIOSYSTEMS | Recombinant Proteins for Biopharma Industry

ChemPartner — Dedicated to LifeScience

Gold Sponsors

Henlius

康龙化成 PHARMARON

GILEAD

AMGEN

Deloitte.

ARAGEN A GVK BIO Company

FINNEGAN

昭衍 JOINN

Silver Sponsors

AbVision THERAPEUTICS

Novogene

BioVision BioVision Incorporated

正大天晴药业集团 CHIATAI TIANQING PHARMACEUTICAL GROUP

cisbio INTERACTION IS EVERYTHING

GenScript Make Research Easy

MabPlex

BGI GLOBAL GENOMIC SERVICES

probe LIFE

Scilligence

FMD FOUNTAIN MEDICAL DEVELOPMENT LTD. 方恩医药发展有限公司

Jemincare Therapeutics

PriMera

Bellen

成都医学城 CHENGDU MEDICAL CITY

BIOBASE®

Q BAY 钱塘中心

Sangamo THERAPEUTICS

10-year Long-term Platinum Sponsor

MORRISON FOERSTER

Platinum Sponsor

药明康德集团
WuXi AppTec Group

Badge Sponsor

EUREKA THERAPEUTICS

Workshop Sponsor

维通达，动物模型专家
VITALSTAR

Exhibitors

Acme Bio
Viracor | Eurofins BioPharma Services
HumanCells Biosciences
ACHEMBLOCK Advanced ChemBlocks Inc
EirGenix
先声药业 Simcere
BIODURO
BizGenius
Northeastern San Francisco | Bay Area
ChemShuttle Synthesizing Life
NEW YORK LIFE 紐約人壽 傅家之保
百奥赛图 BIOCYTOGEN
Protheragen
ASC Applied StemCell Genome editing *in vitro* and *in vivo*
NVIGEN
金前程 Golden Career 人力资源服务外包专家 | 归国圈 Gui Guo Quan 好机会 面对面
J&K Scientific *Integrated Scientific & Industrial Resource Platform*
Accurus Biosciences *Your partner in therapeutic antibody discovery*
Studio
TELEDYNE ISCO Everywhereyoulook
MagStone LAW 牧誠
NeuCyte Translatable Neuroscience
维通达，动物模型专家 VITALSTAR
MOREHealth Access to the world's best healthcare

CABS
Chinese-American Bio/Pharmaceutical Society
北美华人生物医药协会

CABS Contact Information

Mailing Address 邮政地址

268 Bush Street, #1888
San Francisco, CA 94104, USA

Website 网页地址

www.cabsweb.org
www.biopacificconference.org

Email 电子邮件信箱

General information
一般信息
Info@CABSweb.org

Membership 会员申请
Membership@CABSweb.org

Alliance Management 募款
Fundraising@CABSweb.org

Brochure Design
会议手册设计
Xiaojun Li

Brochure Production
会议手册制作
CABS Publication Committee 2019

Our Vision

- *To serve as the gateway linking life science professionals & organizations in the U.S. & Pacific Rim Countries*

Our Mission

- *To SERVE life science professionals to promote professional interactions locally and across the Pacific*
- *To FOSTER business opportunities and exchanges in the life science industry between the U.S. and Pacific Rim countries*
- *To PROMOTE public awareness of progress and development in the life sciences industry*
- *To COLLABORATE with other organizations in areas of mutual interest*

2019 BioPacific Conference Organizing Committee

- **Yang Tian, PhD**, Chair, 2019 BioPacific Conference; President-elect, CABS; Senior Research Scientist, Gilead Sciences
- **Yan Wang, PhD,** President, CABS; Executive Director of Business Development, Kelun Pharmaceutical Research Institute
- **Xu Chen, MS**, Co-Chair, CABS Alliance Management Committee; Business Manager, MaxVision Biosciences
- **Frank Hu, PhD**, Co-Chair, CABS Alliance Management Committee; Senior Customer Support Scientist, Sentieon
- **Chenling Xiong, MD, PhD**, Co-Chair, CABS Public Relations and Communications Committee; Specialist, UCSF
- **Maggie Zhou, MS**, Member, CABS Alliance Management Committee; Associate Scientist, Grail
- **Jin Zhang, MD, PhD**, Member, CABS International Collaboration Committee; Project Manager, Tsingyuan Ventures
- **Yao Yu, MS,** Senior Scientist, Merck
- **Hui Liu, PhD**, Member, CABS Public Relations and Communications; Clinical Research Specialist, Medtronic
- **Hesong Han, PhD,** Co-Chair, CABS Public Relations and Communications Committee; Postdoc fellow, UC Berkeley
- **Han Zhang, PhD,** Co-Chair, CABS Membership Committee; Senior Project Manager, Senti Biosciences
- **Wenming Zhang, PhD,** Co-Chair, CABS Membership Committee; Researcher, Stanford
- **Yuying (Kate) You, PhD, JD,** Chair, CABS Operations Office; Patent Attorney, Morrison & Foerster LLP
- **Simon He, MBA**, Member, CABS Alliance Management Committee; Head of Finance, GenapSys
- **Shaohua Xu, PhD**, Member, CABS Alliance Management Committee; Research Scientist, Eureka Therapeutics
- **Sihong Zhou**, Co-Chair, CABS Social Life Committee; Scientist, Sutro Biopharma
- **Su Dong, PhD**, Member, CABS Social Life Committee; Research Scientist, Gilead Sciences
- **Qiang Gan, PhD**, Co-Chair, CABS International Collaboration Committee; Research Associate, DiaCarta & PAVIR
- **Xiang Yi, PhD**, Co-Chair, CABS Science and Technology Committee; Scientist, Codexis
- **Jenen Tan**, Toast Master President, CABS Business and Career Development Committee; Consultant, IQVIA
- **Michael Xie, PhD**, Co-Chair, CABS Social Life Committee; Chromatography Technical Sales Representative, Teledyne ISCO
- **Jay Lee**, Member, CABS Science and Technology Committee; West Coast Regional Manager, Acrobiosytems
- **Ken Zhang, PhD**, Co-Chair, CABS Science and Technology Committee; Staff Scientist, Pharmacyclics, an AbbVie Company
- **Liping Meng, PhD**, Co-Chair, CABS Business and Career Development Committee; Research Scientist, Gilead Sciences
- **Lisa Zeng, PhD,** Member, CABS Membership Committee
- **Xi Yue, MBA**, Member, CABS Alliance Management Committee; Senior Consultant, Deloitte
- **Wenfeng Xu, PhD**, Co-Chair, CABS International Collaboration Committee; VP of Research, Hengenix
- **Anthony Hsiao, MBA**, Co-Chair, CABS Business and Career Development Committee; Consultant, IQVIA

Graphics and Websites:

- **Xiaojun Li,** Graphic Design/Website Design
- **Michael Lin,** Website Design & Support, Pink Trumpet Associates

CABS Leadership

Board of Directors

Yan Wang, PhD
Alex J. Zhang, PhD, MBA
Cheni Kwok, PhD, CLP
Jiangwen Majeti, PhD, MBA
Alan Hao, PhD
Zhonghua Pei, PhD
Wentao Zhang, PhD
Janet Xiao, PhD, JD
Shichang Miao, PhD
Jing-Shan Hu, PhD
Cheng Liu, PhD
John Wang, PhD

Singapore Founding Advisory Committee

Huck Hui Ng
Executive Director, GIS, A*STAR
Sidney Yee
EVP, ETPL, A*STAR
Lily Chan
CEO, NUS Enterprise
See Kiong Ng
Director of Translational Research and Professor of Practice at NUS
Yih-Cherng Liou
Associate Professor, Faculty of Science, NUS
Andrew Tan
Associate Professor, NTU
Yann Chong Tan
Co-founder, Atreca
Rosemary Tan
CEO, Veredus
Lawrence Wee
Chief Data Scientist, Zuellig Pharma
Robert Tan
Head of Market Access, Alcon, Novartis
Abhijit Ghosh
International Tax Partner leading Pharmaceutical/Life Sciences Tax Practice, PWC
Shirin Tang
Corporate Partner, Morrison Foerster

2019 Executive Council

Office of the President
- President: Yan Wang, PhD, Executive Director of Business Development, Kelun Pharmaceutical Research Institute
- President-elect: Yang Tian, PhD, Senior Research Scientist, Gilead Sciences
- Past President: Alex J. Zhang, PhD, MBA, CEO, Hanhai Silicon Valley

Yan Wang

Yang Tian

Alex J. Zhang

Office of Operations (O2)
- Chair: Yuying (Kate) You, PhD, JD, Morrison & Foerster LLP
- Members: Linlin Xu, PhD, Medimmune; Lily Zhang, MS, Quintana Discovery; Helen Chen, Enterey Inc.

Membership (MEM)
- Co-Chair: Han Zhang, PhD, Senti Biosciences
- Co-Chair: Wenming Zhang, PhD, Stanford
- Members: Shang Li, PhD, University of California, San Francisco; Lisa Zeng, PhD

Public Relations & Communications (PRC)
- Co-Chair: Chenling Xiong, MD, PhD, University of California, San Francisco
- Co-Chair: Hesong Han, PhD, UC Berkeley
- Member: Hui Liu, PhD, Medtronic; Kerui Gong, MD, PhD, BioMarin

Alliance Management Committee (AMC)
- Co-Chair: Xu Chen, MS, MaxVision Biosciences
- Co-Chair: Frank Hu, PhD, Sentieon
- Members: Maggie Zhou, MS, Grail; Shaohua Xu, PhD, Eureka Therapeutics; Simon He, MBA, GenapSys; Jiacong Guo, PhD, Biotrack Capital; Jin Zhang, MD, PhD, Tsingyuan Ventures; Chengya Liang, MD, PhD, MBA, Thermo Fisher; Xi Yue, MBA, Deloitte

Science & Technology Committee (STC)
- Co-Chair: Ken Zhang, PhD, Pharmacyclics, an AbbVie Company
- Co-Chair: Xiang Yi, PhD, Codexis
- Members: Chenling Xiong, MD, PhD, University of California, San Francisco; Jay Lee, Acrobiosytems; Wenyu Luo, PhD, Henlix; Meng Chen, PhD, Lakepharma

International Collaboration Committee (ICC)
- Co-Chair: Wenfeng Xu, PhD, Hengenix
- Co-Chair: Qiang Gan, PhD, DiaCarta & PAVIR
- Members: Di Xue, PhD, Genentech; Michael Xie, PhD, Teledyne ISCO; Suzie Wu, PhD; Bo Lian, PhD, Gilead Sciences; Jin Zhang, MD, PhD, Tsingyuan Ventures; Jiacong Guo, PhD, Biotrack Capital; Furong Yu, PhD, University of California, San Francisco; Lingyi Huang, PhD, CStone Pharma; Qing Zhang, MD, 3E BIOVENTURES; Wendy Cheng, Automation Engineering Systems; Chengya Liang, MD, PhD, MBA

Business & Career Development Committee (BCD)
- Co-Chair: Liping Meng, PhD, Gilead Sciences
- Co-Chair: Anthony Hsiao, MBA, IQVIA
- Chair of Entrepreneur Club: Huijun Zhou, PhD, FACMG, iDNA
- CABS Toast Master President: Jenen Tan, ScM, PhD, IQVIA
- CABS CAN Program Director: Joe Zhang, MD, PhD, Stanford University
- Members: Yonghua Pan, PhD, Sangamo BioSciences; Yan Qi, Morrison & Foerster LLP; Cindy Yang, MBA, Cytokinetics; Lily Zhang, MS, Quintana Discovery; Ravi Mistry, MS, MBA, EPPIC Global Network; Fan Yang, BioMarin; Jing Ye, Wilson Sonsini Goodrich and Rosati; Chengya Liang, MD, PhD, MBA

Social Life Committee (SLC)
- Co-Chair: Sihong Zhou, Sutro Biopharma
- Co-Chair: Michael Xie, PhD, Teledyne ISCO
- Members: Shaohua Xu, PhD, Eureka Therapeutics; Li Li, PhD, Henkel; Lisa Zeng, PhD; Furong Yu,PhD, University of California, San Francisco; Lu Lu, MS, WuXi AppTec; Luqia Hou, PhD, Merck

Regional Representatives
- East Coast Representative: Li Feng, PhD, JD, Finnegan
- Southern California Representative: Yiwen Li, NantHealth
- China Coordinator: Shiming Xu, PhD, Zhejiang University

Web Master:
Michael Lin, Pink Trumpet Associates

Accountant
Yao Long

Graphic Designer
Xiaojun Li



CABS Recognizes Executive Member Contributions

AWARDS

At the Chinese American BioPharmaceutical Society (CABS) Leadership Transition Meeting held on October 28, 2018, CABS President Alex J. Zhang and the 2017-2018 EC leaders reviewed the achievements of the past term, and recognized the contributions from the following EC members:

2018 Extraordinary Leadership Awards

Extraordinary Leadership Awards recognize EC members for more than 5 years serving as Chair or Co-chair at CABS EC Committees. Each awardee receives a complimentary lifetime CABS membership, and free passes to all CABS activities for 5 years starting from November 2018.

Sihong Zhou
(SLC, 2015-present)

Gavin Lu
(AMC, 2015-2017; ICC 2017-2018)

e Council (EC)

2018 Outstanding Leadership Awards

- Xiang Yi (STC and AMC)
- Huijun Zhou (BCD)
- Hui Liu (AMC)
- Frank Hu (AMC)
- Jiacong Guo (ICC)
- Michael Xie (SLC)
- Wenming Zhang (MEM)
- Linlin Xu (O2)

Outstanding Service Awards recognize outstanding service performed by EC members during the 2017-2018 term. Each awardee receives 2-year complimentary CABS membership, or a free pass to 2019 BioPacific Conference if a lifetime member.

2018 Special Contribution Awards

Special Contribution Awards recognizes extraordinary contributions to CABS in the 2017-2018 EC Term



Xu Chen
AMC

Qiang Gan
ICC

Yang Tian
PRC

About CABS

Who We Are

The Chinese American Biopharmaceutical Society (CABS) is a non-profit organization for professionals in the biopharmaceutical industry. CABS is headquartered in San Francisco Bay Area, California. This is the home of the Silicon Valley, the birthplace of biotechnology and one of the largest biomedical clusters with the highest venture capital investment in the world. There are more than a thousand biopharmaceutical/biotech companies in this area, including several large biopharmaceuticals such as Amgen, Genentech and Gilead. CABS is a highly influential association with more than 3000 members and subscribers in the life sciences industry. About 70% of our members have PhD degrees relating to life sciences. A considerable proportion of the members hold senior research and management positions in US-based and multi-national life sciences corporations. Many of our members are experts and leaders, innovative entrepreneurs, lawyers and venture capitalists or investors in the life sciences sector. CABS is the largest and most active Chinese biopharmaceutical association in North America. We organize many activities to promote international collaborations in life sciences and to provide Science & Technology Parks and life sciences companies in Asia Pacific countries with an excellent platform to promote business and to recruit talent. In addition to year-round technology and business seminars, the annual BioPacific Conference organized by CABS is a highly anticipated event that attracts hundreds of biopharmaceutical professionals and business leaders.

TABLE OF CONTENTS

The official working language of the conference is English

WELCOME

Yan Wang, PhD
President of CABS

Remarks from the President of Chinese American BioPharmaceutical Society (CABS)

Welcome to the 2019 BioPacific Conference, the 21st annual conference of Chinese American Biopharmaceutical Society (CABS)!

On behalf of everyone at CABS, I would like to express our sincere gratitude to all the speakers and sponsors for their support of our association and this conference. Special thanks to President-elect and the 2019 BioPacific Conference Organizing Committee Chair, Dr. Yang Tian, the Conference Organizing Committee members, and all the volunteers for their passion, dedication, diligence and hard work to make this conference possible and successful.

2018 has been a fantastic year for the biopharmaceutical industry with record FDA approvals and a booming biotech IPO market. The FDA's Center for Drug Evaluation and Research (CDER) approved 59 novel drugs in 2018, breaking its record of 53 drugs in 1996. The NASDAQ showed a record amount of biotech initial public offerings (IPOs) last year, including some individual record-breakers. There were significant advancements in the cutting-edge science and technology, as well as active investment, licensing deals and M&A in life science. Our esteemed speakers will cover these topics in their speeches and panel discussions.

It is our great honor to recognize the extraordinary achievements of Mr. John V. Oyler, the awardee of 2019 CABS Ken Fong Award in Life Sciences. Mr. Oyler is a legendary entrepreneur. Under his leadership, BeiGene has transformed into one of China's most innovative biotech companies and a global biopharmaceutical company covering the full biopharma value chain, from R&D and clinical development, to manufacturing and commercial operations within a decade. We also appreciate Mr. Oyler's and BeiGene's continuous support of CABS in the past years and in the future.

CABS has been serving as a gateway connecting life sciences professionals and companies in the past 21 years. We are here today to celebrate the excellence of CABS. It has been such an honor and privilege to serve as President and to work with 2018-2019 CABS Executive Council and the volunteers. In the past year, we successfully organized a number of high-quality events including the CABS signature forum "2019 CABS Investor Forum" during JP Morgan Healthcare Conference and symposiums on "CAR-T and cell therapy", "Small molecule drug discovery", "Therapeutic antibody technology and development", "Preclinical and early phase development of biologics and small molecules", and "Artificial intelligence and precision medicine: the next revolution in healthcare", which are all very well received. We will continue to offer more opportunities for life science professionals to learn and network.

Once again, thank you all for the unyielding support! Please enjoy 2019 BioPacific Conference!

Sincerely,

yanwang

Yan Wang
PhD, President of CABS

Yang Tian, PhD
Chair of 2019 BioPacific Conference Organizing Committee,
President-elect of CABS

Remarks from the Chair of 2019 BioPacific Conference Organizing Committee

Welcome to 2019 BioPacific Conference! It is my great honor to serve as Organizing Committee Chair and work with everyone to organize 2019 BioPacific Conference, which is also the 21st Annual Conference of Chinese American Biopharmaceutical Society (CABS).

The theme of 2019 BioPacific Conference is Pursing Science for Cure, a reflection of multiple breakthroughs in basic medical sciences and translation into innovative medicines in the past few years. This year's conference will feature talks on the science-driven drug discovery efforts in the most difficult diseases such cancer, infectious disease and neurodegenerative diseases. The 2019 CABS K. Fong Award winner will give an award speech on the perspective of pharmaceutical innovation in next decade. With increasing regulations on foreign investment in US technologies, we will have a featured talk on recent CFIUS regulations and a panel discussion on the best strategy to navigate those new regulations. There will be presentations and panel discussions on cutting-edge science and technologies including cancer immunotherapy, precision medicine and translational sciences. BioPartnering opportunities will also be available at this conference to facilitate collaborations.

I would like to take this opportunity to express our gratitude to everyone for making this conference possible.

First, I sincerely thank our 26 esteemed speakers who took time from their busy schedules to share their expertise at this conference. Second, we are very grateful that 57 companies are supporting our conference this year. CABS events, particularly BioPacific Conference, serve as an excellent interactive platform to engage professionals and companies in the life science community from startups to global pharmaceutical companies. Thank you to all the sponsors for their generous support. Third, I would like to give special recognition to our amazing volunteers. They have worked tirelessly for the past months with passion, dedication, diligence and perfectionism.

Thank you so much for making our conference a great success!

Most important of all, we are very grateful to all the attendees of this conference. We truly appreciate your support to CABS and for being here today. All of us at CABS hope you will enjoy the conference and the post-conference evening networking event with live band. Thank you ALL!

Yang Tian, PhD
Chair of 2019 BioPacific Conference Organizing Committee
President-elect of CABS

2019 BIOPACIFIC CONFERENCE

AGENDA June 22, 2019

Theme: Pursuing Science for Cure

The official working language of the conference is English

8:00am – 8:40am	**Registration**
Morning Session I	**Session Chair: Yang Tian**
8:40am – 8:45am	**Welcome Remarks** **Yang Tian, PhD,** *President-elect of CABS and 2019 BioPacific Conference Organizing Committee Chair*
8:45am – 8:50am	**State of the Society** **Yan Wang, PhD,** *President of CABS*
8:50am – 9:20am	**Keynote: Biomarkers and Translational Research in Cancer Therapy** **Ron Mazumder, PhD, MBA,** *Vice President and Global Head of Oncology Biomarker Development and Companion Diagnostics, Genentech*
9:20am – 9:50am	**New Diagnostics Ecosystem to Accelerate Drug Discovery and Medical Innovation** **Jason Liu, PhD, MBA,** *CEO, WuXi Diagnostics*
9:50am – 10:40am	**CABS K. Fong Award in Life Sciences** **Introduction: Wentao Zhang, PhD,** *CEO, Quintara Discovery* **Presenter: Kenneth Fong, PhD,** *Chairman, Kenson Ventures* **Award Speech: The Future of the Biopharma Industry: Innovation Beyond Science** **Awardees: John Oyler, MBA,** *Founder, CEO and Chairman of BeiGene*
10:40am – 11:00am	**Coffee Break and Networking**
Morning Session II	**Session Chair: Xiang Yi**
11:00am -11:30am	**Designing Therapies to Cure HIV** **Romas Geleziunas, PhD,** *Executive Director, Gilead Sciences*
11:30am – 11:40am	**Fireside Chat** **Moderator: Alex J. Zhang, PhD, MBA,** *CEO, Hanhai Silicon Valley* **Jun Xiang, PhD,** *General Manager, ChemPartner Biologics*
11:40am - 12:00pm	**Key Developments: CFIUS, Export Control Reform, and Recent Decisions Affecting Life Sciences Investment and Licensing** **Joseph Benkert,** *Senior Advisor, National Security Group, Morrison & Foerster*
12:00pm -12:30pm	**Panel Discussion: IP, Legal and Investment in Life Sciences** **Moderator: Huijun Zhou, PhD, FACMG**, *Founder and CEO, iDNA* **Panelists: Joseph Benkert,** *Senior Advisor, Morrison & Foerster* **Greg Scott,** *Founder and Chairman, ChinaBio* **Michael Su, MS, JD,** *Attorney, Intellectual Property Law, Finnegan* **Vivien Wang, MS,** *Partner, Deloitte*

12:30pm -1:30pm	**Lunch Break**
12:50pm - 1:30pm	**Sponsor Workshop: Humanized Mouse Model Accelerates Biomedicine Research & Drug Development (Synergy 1 Room)** **Ming Yin, PhD, MBA,** *VP, Beijing VitalStar Biotechnology*
Afternoon Session I	**Session Chair: Jin Zhang**
1:30pm – 2:00pm	**New Approaches To Neurodegenerative Disease Drug Discovery and Development** **Zach Sweeney, PhD,** *Head of Therapeutic Discovery, Denali Therapeutics*
2:00pm - 2:30pm	**Panel Discussion: Innovative and Collaborative Contract Services to Accelerate Drug Development** **Moderator: Jiangwen Majeti, PhD, MBA,** *Genentech* **Panelists: Tao He, PhD,** *Co-Founder and SVP, JOINN Biologics* **Connie Sun, PhD,** *SVP, Pharmaron* **Mike Chen,** *CEO, AcroBio*
2:30pm – 3:00pm	**Applying Precision Medicine One Patient at a Time** **Shivaani Kummar, MD,** *Professor of Medicine and Director of Phase I Clinical Research Program (Oncology), Stanford University*
3:00pm – 3:20pm	**Coffee Break and Networking**
Afternoon Session II	**Session Chair: Frank Hu**
3:20pm – 4:20pm	**Panel Discussion: Innovative Therapy in Oncology, What is Next?** **Moderator: Cheni Kwok, PhD, CLP,** *Managing Partner and Founder, Linear Dreams* **Panelists: Wenfeng Xu, PhD,** *VP of Research, Henlius* **Jean Cui,PhD,** *CSO, Turning Point Therapeutics* **Mark Nevins, MS,** *VP of Business Development, Apexigen* **Peiwen Yu, PhD,** *VP of Discovery Biology, Exelixis* **Tara Arvedson, PhD,** *Director of Research, Amgen* **Yanyan Zheng, PhD,** *Principle Scientist, Merck*
4:20pm – 4:50pm	**Talazoparib: From Virtual Drug Discovery to FDA Approval** **Leonard Post, PhD,** *CSO, Vivace Therapeutics*
4:50pm	**Conference Adjourned**
5:00pm – 7:00pm	**Post-conference Reception Sponsored by Diamond Sponsors (Engage room and courtyard)**
8:40am – 4:40pm	**Conference (Convene room)**
8:40am – 7:00pm	**Partnering (Synergy 1 and 5 room)**
8:00am – 7:00pm	**Exhibition hall (Inspire room)**

2019 BIOPACIFIC CONFERENCE

Floor Plan - San Mateo Marriott

1770 South Amphlett Blvd., San Mateo, CA 94402

- The main conference
- Exhibition
- Partnering Program
- Lunch Workshop

The evening reception will be on Level 1, in Engage Room and the Courtyard.

Conference Floor Plan





Note:
- Standard Aisle space is 6’ per fire code
- Please follow the angle and position of the tables
- Fire exits must be visible and not blocked
- Diagram is not to scale

Exhibition Floor Table Plan

Announcing 2019 CABS K. Fong Award in Life Sciences

The Chinese American Biopharmaceutical Society (CABS) K. Fong Award Committee is very pleased to announce that ***JOHN V. OYLER*** *is the winner of the 2019 CABS K. Fong Award in Life Sciences for his entrepreneurship and business leadership to establish BeiGene as a world-class biopharmaceutical company. We will honor Mr. Oyler in the award ceremony at the 21st CABS Annual Meeting of the BioPacific Conference to be held on Saturday, June 22, 2019 at the San Mateo Marriott San Francisco Airport Hotel (1770 South Amphlett Blvd., San Mateo, CA 94402).*

About CABS K. Fong Award in Life Sciences

CABS K. Fong Award in Life Sciences is presented annually to recognize those individuals who make significant contributions in the life sciences and biopharmaceutical industry including outstanding scientific findings, recognized efforts in promoting life science education and initiatives in improving life science community, and those who bring therapeutic breakthroughs to the market and improve healthcare and quality of life. Candidates must be nominated by an active member of CABS. Selection criteria will be based on candidate's accomplishments in life sciences and contribution to the life science community, including one or all of the following:

- Proven achievements in therapeutic breakthroughs (including discovery, process or clinical development), diagnostics or the research reagent/equipment markets.
- Significant contribution to the promotion of academic and industrial R&D in biomedical sciences and applications.
- Significant contribution to the CABS community and to promoting international collaboration in life sciences.

CABS K. Fong Awardee

Mr. John V. Oyler

John V. Oyler is the Chairman, Co-Founder and CEO of BeiGene. BeiGene is a global, commercial-stage biopharmaceutical company focused on the development of molecularly-targeted and immuno-oncology cancer therapeutics. Founded originally as a R&D company in 2010 by Mr. Oyler and renowned scientist Dr. Xiaodong Wang, BeiGene is listed on both the NASDAQ and the Hong Kong Exchange. Under Mr. Oyler's leadership BeiGene has transformed into a global biopharmaceutical company covering the full biopharma value chain, from R&D and clinical development, to manufacturing and commercial operations. The company currently has three late-stage clinical assets with near-term global commercial opportunities and three marketed cancer products licensed in China. The past nine years has seen tremendous growth at BeiGene; today, the company has 10 offices located in four countries and employs more than 2,200 people across the globe. BeiGene truly epitomizes the ongoing integration of China and the U.S. in science and technology, which resonates with the mission we serve at CABS.

From 2005 to 2009, Mr. Oyler served as President and Chief Executive Officer of BioDuro, LLC, a drug discovery outsourcing company, which was acquired by Pharmaceutical Product Development Inc. in 2010. From 2002 to 2004, Mr. Oyler served as Chief Executive Officer of Galenea Corp., a biopharmaceutical company dedicated to the discovery of novel therapies for central nervous system diseases, which initially were developed at the Massachusetts Institute of Technology. From 1997 to 2002, Mr. Oyler was a Founder and the President of Telephia, Inc., which was sold to The Nielsen Company in 2007. From 1997 to 1998, Mr. Oyler served as Co-Chief Executive Officer of Genta Incorporated (NASDAQ: GNTA), an oncology focused biopharmaceutical company. Mr. Oyler began his career as a management consultant at McKinsey & Company. Mr. Oyler received his B.S. from Massachusetts Institute of Technology and MBA from Stanford University.

Past recipients of CABS K. Fong Awards

2018 **Dr. Yuling Luo,** Founder, CEO and Chairman of Alamar Biosciences, and **Dr. Guoliang Yu**, Executive Chairman of Crown Bioscience, for their successful serial entrepreneurship in the life science business.

2017 **Dr. Yinxiang Wang**, Founder of Zhejiang Beta Pharma, and **Dr. Edgar Engleman**, Professor of Medicine at Stanford University, for their extraordinary achievements in research, entrepreneurship, and innovation.

2016 **Dr. Gerald Chan**, Co-founder of Morningside, for his extraordinary vision and leadership in cultivating a generation of successful entrepreneurs and life sciences companies.

2015 **Dr. Irving Weissman**, Stanford University, for his pioneering research in stem cell research.

2014 **Dr. Ge Li,** Founder and CEO of Wuxi Apptec, for creating and shaping the CRO business model in China and **Dr. Hing L. Sham**, formerly of Abbott for his leading role in the discovery of life-saving HIV protease inhibitors, ritonavir and lopinavir.

2013 **Dr. Peter Hirth,** Plexxikon & Sugen for his pivotal role in advancing 4 successful drugs to the market, and **Dr. Jean Cui,** formerly of Pfizer for her role as the lead designer and investigator of crizotinib, a successful kinase inhibiting drug used in personalized medicine.

About Dr. Kenneth Fong

Dr. Kenneth Fong has spent the last 32 years in the biotech industry after completing his academic pursuit in biomedical research.

He is best known for founding the biotech company, Clontech in 1984 where he had cultivated it to be one of the largest biomedical tool companies founded by an Asian American in the US (400 people with 65 PhD scientists). Clontech was sold to Becton Dickinson in 1999 and Ken has continued his career as a Venture capitalist with Kenson Ventures that he founded. He has since cultivated more than 10 highly successful entrepreneurs, advising them and working with them on the growth of their companies.

Currently, he sits on the board of four biotech companies and he was intimately involved with the M/A and IPO of more than 10 companies that are worth north of $3 billion. These companies range from research tools, medical diagnostics and drug development. In almost all cases, Dr. Fong has been instrumental in providing strategies for sustainable growth, value creation and liquidity. Those successful entrepreneurs have moved on to assume leadership in other start-up and mid-sized companies, which in turn leads to a new generation of entrepreneurs.

Ken has held a number of leadership positions over the years. He served as the President of the Society of Chinese Bioscientists in North America (2006-07) and President of the Bay Area Asian American Manufacturers' Association (AAMA, 1987). He was also the member of the Board of Trustees of the California State University System (2006-13). His philanthropic interests include scholarships to San Francisco State University, the Kenneth Fong-Hearst endowed scholarships to the CSU system and 40 student scholarships to Peking University. In 2006, he was involved with establishing the Fong Optometry and Medical library at UC Berkeley, and more recently an endowed professorship at Stanford University and a technology translation endowed fund at San Francisco State University.

Ken obtained his PhD from Indiana University and his BS from San Francisco State University.

2019 BIOPACIFIC CONFERENCE

SPEAKERS

Keynote:

Biomarkers and Translational Research in Cancer Therapy

Ron Mazumder, PhD, MBA
VP, Global Head of Oncology Biomarker Development and Companion Diagnostics, Genentech

Abhijit "Ron" Mazumder obtained his B.A. from The Johns Hopkins University, his PhD from the University of Maryland, and his MBA from Lehigh University. After working in several biotech companies, he joined Johnson & Johnson in 2003 and led molecular diagnostics programs and biomarker collaborations. In 2008, he joined Merck as a Senior Director and Biomarker Leader in External Discovery where he was responsible for the development of pharmacodynamic and predictive biomarkers. Ron rejoined Johnson & Johnson in 2010 and led the development of companion and complementary diagnostics across the therapeutic pipeline. In October 2016, he joined Genentech where he is currently Vice President and Global Head of Oncology Biomarker Development and Companion Diagnostics.

Abstract: Predictive biomarkers and translational research can be used to help identify patients most likely to derive benefit from therapeutic regimens and to inform new combination regimens. Focusing on immuno-oncology, I will provide examples and perspectives of current and future research in this area.

Presentation Title:

New Diagnostics Ecosystem to Accelerate Drug Discovery and Medical Innovation

Jason Liu, PhD, MBA
CEO, WuXi Diagnostics

Jason Liu is a seasoned executive with nearly 30 years of experience in life science industry, including 20 years of senior leadership in multinational clinical diagnostics and medical device companies. Dr. Liu has extensive experience in cross-culture business integration, merger & acquisition, new business development, international investment, post-merger integration, and operation. Dr. Liu joined WuXi AppTec Group in 2014 as Senior Vice President and Division Chief Operation Officer. He established the Lab Testing Division (LTD) through integrated testing platforms in China and US, rapidly expanded its global operation, and enhanced LTD's leading position in pharmaceutical and medical device testing sector. In January 2018, Dr. Liu led teams to establish WuXi Diagnostics (WXDX), a joint venture between WuXi AppTec Group and Mayo Clinic. He became the CEO for WuXi Diagnostics on Jan 1st, 2019.

Before joining WuXi AppTec Group, Dr. Liu worked at Hologic-Gen Probe, Life Technologies-Applied Biosystems, and Bio-Rad as regional GM for APAC and China, global business unit GM at US headquarters.

Dr. Liu received his Ph.D. in Molecular Biology & Human Genetics from Loma Linda University, MBA from Pepperdine University, and BA in Biochemistry from Shandong University, China.

Abstract: The increasing cancer incidence and mortality accelerate demand for targeted drugs and companion diagnostics and economic pressures to develop maximally efficient treatments in China. With the encouragement from the China government, it's estimated that by 2021, the market size of companion diagnostics will reach 741 million USD, with CAGR of 28%, far exceeding the global scale as 20.1%.

WuXi Diagnostics enables precision medicine through a unique dual-enabling platform for in-vitro diagnostic service and product innovation. Our advanced platform integrates multi-dimensional, multi-omics medical data to generate deep clinical insights, and pioneer innovation by building a novel eco-system for healthcare industry.

Award Speech:

The Future of the Biopharma Industry: Innovation Beyond Science

John V. Oyler, MBA
Co-Founder and CEO, BeiGene, Ltd.

John V. Oyler Co-Founded BeiGene, Ltd. and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive Officer and President from 2005 to 2009. He co-founded Telephia, Inc. (now Nielsen Mobile, Inc.) and served as its President from 1997 to 2002. He served as Chief Executive Officer of Galenea Corp. from 2002 to 2004. Mr. Oyler served as the Co-Chief Executive Officer of Genta, Inc., from 1997 to 1998. Mr. Oyler began his career as a management consultant at McKinsey & Company. Mr. Oyler serves as the Chairman at BeiGene, Ltd. and has been its Director since 2010. Mr. Oyler earned an MBA from the Stanford Graduate School of Business and a Bachelor of Science degree in Mechanical Engineering from MIT.

Presentation Title:

Designing Therapies to Cure HIV

Romas Geleziunas, PhD
Executive Director, Biology, Gilead Sciences

Romas Geleziunas is an Executive Director in the Biology department at Gilead Sciences. Dr. Geleziunas received his Ph.D. in Microbiology and Immunology from McGill University (Montreal, Canada) and conducted post-doctoral studies at UCSF. Dr. Geleziunas has worked on HIV for 32 years in academia and the pharmaceutical industry, and is an author on 83 scientific articles. At Gilead, Dr Geleziunas has led multidisciplinary HIV antiviral drug discovery and early drug development programs for the past 14 years. He established and led Gilead's HIV eradication program and is currently the head of the HIV clinical Virology group. Prior to joining Gilead, he worked on a number of drug discovery programs at Dupont Pharmaceuticals (acquired by Bristol-Myers Squibb) and Merck Research Laboratories.

Abstract: Combinations of antiretroviral drugs (ARVs) are used to treat people with HIV infection, and their use prevents progression to AIDS. Unfortunately, ARVs do not cure HIV, hence people living with HIV must take ARVs for life. The establishment of a long-lived viral reservoir in memory CD4+ T-cells that is impervious to ARVs is the reason for life-long therapy. Gilead has been working on therapeutic strategies to eradicate HIV infection for about a decade. The program is centered on immune-based therapies that are comprised of combinations of TLR7 agonists, monoclonal antibodies targeting the HIV envelope protein and therapeutic vaccines capable of inducing HIV-specific CD8 T-cell responses.

Presentation title:

Key Developments: CFIUS, Export Control Reform, and Recent Decisions Affecting Life Sciences Investment and Licensing

Joseph Benkert
Senior Advisor, National Security Group, Morrison & Foerster

Joseph Benkert is a senior advisor in Morrison & Foerster's National Security practice group. He advises clients on critical national security matters pertaining to the Committee on Foreign Investment in the United States (CFIUS), export controls, and various regulatory and compliance issues. Mr. Benkert previously served as a leading civilian official in the Department of Defense (DoD) under both the Bush and Obama administrations, including as Assistant Secretary of Defense for Global Security Affairs after being nominated by President Bush and confirmed by the Senate. While at the DoD, Mr. Benkert led the department's involvement in numerous complex matters before CFIUS. Mr. Benkert's responsibilities also included managing technology security policy, the reform of export control processes, numerous sensitive nonproliferation projects, and a broad range of other defense-related issues. More recently, Mr. Benkert served as a Vice President of a leading global consultancy group, under former Secretary of Defense William Cohen. Mr. Benkert was a career Navy officer with extensive experience both in operational command and in national security policy formulation and implementation.

Abstract: Legislation enacted late last summer put in motion potentially significant changes to the review of inbound investments by the Committee on Foreign Investment in the United States (CFIUS) and export control for outbound licensing, joint ventures and other arrangements. CFIUS subsequently issued regulations creating a pilot program to implement changes related to critical technologies, and the Commerce Department issued a notice to begin defining and possibly controlling such technologies. Further regulations implementing these changes are on the way in the coming months, and recently, CFIUS was reported to be forcing the unwinding of several closed transactions, including one in the life sciences sector. These developments in CFIUS and export control take place in the context of ongoing trade tensions between the U.S. and China, which many see as affecting the cross-border investment climate as well. This podium talk will provide updates on recent developments, what to expect in the months ahead, the effects on cross-border investment and licensing in general and life sciences in particular, and how to navigate these changing circumstances.

Presentation title:

New Approaches To Neurodegenerative Disease Drug Discovery and Development

Zach Sweeney, PhD
Head of Therapeutic Discovery, Denali Therapeutics

Zach Sweeney leads the Therapeutic Discovery group at Denali. In this role, he supports the discovery chemistry, protein engineering, protein sciences, antibody discovery, AAV-discovery, discovery pharmacology and discovery data sciences teams.Before joining Denali, Zach was a Director of Global Discovery Chemistry and Head of Analytical Chemistry at Novartis Emeryville. Zach also worked as a scientist and team leader at Genentech and Roche. His project teams have contributed to the identification of more than a dozen candidates that have entered IND-enabling studies, and five of these molecules have progressed into clinical studies. He has also co-authored more than 60 patent applications and 35 scientific articles. Zach graduated with a degree in chemistry from Stanford University, received a Ph.D. in chemistry from the University of California, Berkeley, and completed a NIH-postdoctoral fellowship at Harvard University.

Abstract: Significant advances in our understanding of the genetics, pathology and cell biology associated with neurodegenerative diseases have identified biological pathways that contribute to disease onset and progression. Denali Therapeutics has developed a portfolio of novel drug candidates that modulate several of these pathways, including microglial function, lysosomal function, and the cellular stress response. This presentation will provide an overview of selected development programs and our research and development principles, including our emphasis on leveraging genetic information to guide our therapeutic approach, and focusing clinical development through the discovery and use of biomarkers.

Presentation title:

Applying Precision Medicine One Patient at a Time

Shivaani Kummar, MD
Professor of Medicine, Stanford University

Shivaani Kummar is Professor of Medicine and Director of the Phase I Clinical Research and Translational Oncology Programs at Stanford University. Prior to joining Stanford in 2015, Dr. Kummar served as the Head of Early Clinical Trials Development in the Office of the Director, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland. Her research interests focus on developing novel therapies for cancer, conducting pharmacokinetic and pharmacodynamic driven first-in-human trials. The clinical studies integrate genomics, imaging, and laboratory correlates into early phase trials. She serves on multiple national and international scientific committees and has published more than 125 papers in peer review journals.

Abstract: Dramatic responses to targeted agents, durable responses to checkpoint inhibitors, identification of potential new therapeutic targets, and modifications to the regulatory framework, have generated a growing excitement for anticancer drug development. With the increasing number of therapeutic choices, we need to improve our ability to tailor these therapies for individual patients most likely to derive clinical benefit with a high safety margin. In this talk I will discuss emerging biomarkers for immune based therapies, recent data on genomic drivers, and the considerations around applying precision medicine in the clinic for an individual patient.

Presentation title:

Talazoparib: From Virtual Drug Discovery to FDA Approval

Leonard Post, PhD
Chief Scientific Officer, Vivace Therapeutics

Leonard Post is Chief Scientific Officer of Vivace Therapeutics, a company focused on drug discovery in the hippo pathway. Before Vivace he was CSO of BioMarin. Len was involved in the discovery of the PARP inhibitor talazoparib while CSO of LEAD Therapeutics, and continued working on the compound in preclinical development through the beginning of Phase 3 while at BioMarin. Prior to LEAD he was SVP of R&D at Onyx Pharmaceuticals, and before that had positions at Parke-Davis Pharmaceuticals and The Upjohn Company. He is currently on the boards of directors of Orphagen, Fedora, Oxyrane, and ColdGenesys. Prior board positions include Praecis, BioVex, and Viralytics. His training included a PhD in Biochemistry and postdoctoral research in virology.

Abstract: LEAD Therapeutics was founded in 2007 to do virtual drug discovery by using strengths of both the US and China. The most successful project was the discovery of a PARP inhibitor, talazoparib, that led to acquisition of LEAD by BioMarin. Talazoparib resulted from an extensive medicinal chemistry program beginning with known PARP inhibitor scaffolds but evolving in novel directions. Surprisingly, talazoparib was 100-10,000 fold more potent in tumor cell killing than other PARP inhibitors in clinical development at the time, even though the compounds all have similar potency for inhibition of PARP enzymatic and cellular activity. This greater potency was not understood until researchers at NCI characterized the ability of PARP inhibitors to trap PARP onto damaged DNA. The clinical program conducted across three successive companies led to approval of talazoparib in 2018 for breast cancer patients with germline deleterious brca mutations.

Sponsor Workshop:

Humanized Mouse Model Accelerates Biomedicine Research and Drug Development

Ming Yin, PhD
VP, Beijing VitalStar Biotech

Ming Yin obtained her PhD in Basic Veterinary Medicine, MBA (technology commercialization) at Cambridge and Warwick universities in the UK with a Chevening Scholarship. Used to be the Grand Challenges in Global Health Project Manager of Bill & Melinda Gates Foundation, experienced in humanized animal model and its applications. Currently Ming is VP of Beijing VitalStar Biotech. Ltd, with over 10 years' experience in Business Development, R&D and Licensing/Partnering Activities in the Biotechnology Industry.

Abstract: Spontaneous, induced or genetically engineered mouse tumors and derived cell lines, as well as syngeneic allografts, provide approaches to understand the mechanisms of tumorigenesis, disease development, and metastasis, or to carry out proof of concept study of novel cancer therapies. In addition, the target gene humanized mice may serve as in vivo evaluation models for many cancer immunotherapeutic drugs, such as immune check point inhibitors, bispecific T cell engaged (BiTe) antibodies, and so on. Human tumor cell line-derived xenografts (CDX) and patient-derived xenografts (PDX) on immunodeficient mice allow in vivo screening of some anti-tumor drugs that directly kill cancer cells. But defect in immune system restricts their application in IO study. Humanized immune system mouse models established through engraftment of human peripheral blood mononuclear cells or hematopoietic stem cells, plus CDX or PDX, represent prospective IO models allowing in vivo evaluation of many cancer immunotherapies and reconstitution of immune microenvironment of human tumors to some extent, helping to elucidate the interaction between tumor and immune system. Tumor and immune system-dual humanized mouse models have been successfully applied to efficacy study of novel anti-cancer drugs or treatments, such as immune modulator antibodies, targeting antibodies, BiTe antibodies, CAR-T therapies, protection of cytokine release storm, and so on. Although there are still some restrictions for these humanized mouse models, many efforts are being made to solve the defects by developing next generation models.

Panel Discussion

Fireside Chat

Jun Xiang, PhD
General Manager, ChemPartner Biologics (Shanghai) Co., Ltd.

Jun Xiang has near 20 years' experience in R&D of biological drug products, and is the General Manager of ChemPartner Biologics (Shanghai) Co., Ltd. which provides one-stop CDMO services for biologics, covering from development of cell line, cell culture and purification process, and formulation to pilot-scale and commercial scale manufacturing. Prior to joining CPB, Dr. Xiang was a Sr. VP of Biotechnology Institute of Shanghai CP Guojian (Now name changed to Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd.). He was responsible for research and development of novel formulations and drug delivery systems as well as late stage production processes for antibody drug products. He was also in charge of the entire development of antibody-drug conjugates (ADC), and has established ADC technology platform in CP Guojian along with completion of one ADC drug product IND filing. Dr. Xiang previously worked as a Staff Scientist at Bayer HealthCare Pharmaceuticals in US. He has tremendous experience in late stage development of biological drug products, especially in the various CMC fields. He served as the President of Chinese American Biopharmaceutical Society (CABS) from 2005 to 2006, and was a Board member of CABS from 2004 to 2018. He was also the Chief Managing Editor of the journal Trends in Bio/pharmaceutical Industrial from 2008 to 2011.

Alex J. Zhang, PhD, MBA
CEO, Hanhai Silicon Valley

Alex J. Zhang is the CEO of Hanhai Silicon Valley, an early stage investor and cross-border accelerator for startups in San Francisco Bay Area. Prior to Hanhai, Alex was the Managing Partner of Enverest, LLC., a Silicon Valley-based innovation solutions and investment advisory firm with branch offices in China and Singapore. Prior to co-founding Enverest, Dr. Zhang spent nearly five years at Thermo Fisher Scientific, where he was responsible for four business development deals exceeding $10 M, and played a key role in several billion-dollar acquisitions in MedTech. From 2001 to 2009, Dr. Zhang was a Senior Scientist at Tularik Inc. (acquired by Amgen in 2004), where he led drug discovery endeavors in oncology, cardiovascular and metabolic diseases therapeutic areas.

Dr. Zhang received an MBA degree at Cornell University, PhD in Organic and Analytical Chemistry at Texas A&M University, and BS in Chemistry at Shandong University. During his graduate research, he focused on the design and synthesis of therapeutic peptoids, as well as biological mass spectrometry. His research has led to publication of more than 20 peer reviewed articles and 4 patents.

Dr. Zhang has served multiple leadership roles in the Executive Council of CABS, including as President in 2017-18. Over the past decade, Dr. Zhang has advised a number of successful MedTech and digital health startups based in Silicon Valley.

Panel Discussion

IP, Legal and Investment in Life Sciences

Vivien Wang, MS
Partner, Deloitte

Vivien Wang has over 20 years of public accounting and international tax experiences, providing tax consulting, compliance and tax accounting assurance services to various high-tech, biotech and venture capital clients. Her experience includes structuring and globally managing both U.S. inbound and outbound investments. Vivien specializing in the IPO restructuring, merger and acquisition integration and implementation of worldwide IP migrations and supply chain strategies for multinational clients.

Vivien is our US Inbound Practice leader for the West Region, focusing on serving foreign company's investments in the US through both M&A and greenfield investment. Vivien is also the National Tax Leader of Deloitte's US Chinese Services Group, specializing in China strategy planning for US companies and investment funds and US inbound investment planning for China based investors. In this role, Vivien serves many leading Asia based private equity and venture capital firms, and technology companies and their investments in the U.S. Vivien obtained her MS in Taxation at San Jose State University, BS in Accounting from University of Utah and BA in International Finance, Shenzhen University.

Greg Scott
Founder and Chairman, ChinaBio Group

Greg Scott founded ChinaBio® Group in 2007 to help life science companies and investors achieve success in China. ChinaBio® works with US, European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China. ChinaBio® has also organized over 30 conferences in China focused on cross-border investment and partnering, including the ChinaBio® Partnering Forum which draws over 1400 attendees from around the world to China each spring. Greg is also co-founder of two investment groups that have funded over 50 biotechnology and medical device companies in the US and China, and Executive Editor of ChinaBio® Today, a widely read newsletter covering the China life science industry. He also is the current chair for the American Chamber of Commerce Healthcare Committee, and a former board member of BayHelix Group. Greg is considered a leading expert on China's life science industry and is frequently quoted in media including the Wall Street Journal, Financial Times, Bloomberg, BioWorld, BioCentury, and other industry publications. Headquartered in Shanghai, ChinaBio® has team members in San Diego, Palo Alto, and Basel, Switzerland.

Huijun Zhou, PhD, FACMG
Founder & CEO, iDNA

Huijun Zhou is the CEO and co-founder of Doctor Chain and iDNA.com.cn. Dr. Zhou received her Ph.D. in molecular biology and genetics from Cornell University and completed her post-doctoral medical genetics training at the Stanford University School of Medicine. She is a clinical molecular geneticist, board-certified by the American Board of Medical Genetics. She is the Program Chair of Chinese American Bio-Pharmaceutical Society (CABS) Entrepreneurship Club.

Panel Discussion
Innovative & Collaborative Contract Services to Accelerate Drug Development

Michael Liu Su, MS, JD
Attorney, Intellectual Property Law, Finnegan

Michael Liu Su is an attorney at intellectual property law firm Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. Based in Finnegan's Palo Alto office, Mike's practice spans both patent and trade secret matters, involving industries such as biotechnology, pharmaceuticals, chemical, medical devices, and computer technology. His litigation experience includes representing clients before state and federal trial and appellate courts, and before arbitrators. He has also successfully litigated before the Patent Trial and Appeal Board (PTAB) in post-grant proceedings that involve patent validity. He also maintains an active patent procurement and due diligence practice. In his graduate work, Mike focused on cancer research at the cellular level, specifically in the areas of cell cycles, cell migration, and cancer metastasis. Mike earned an M.S. in genome sciences from National Yang-Ming University in Taiwan and a J.D. from U.C. Berkeley, School of Law.



Connie Sun, PhD
SVP, Business & Corporate Development , Pharmaron

Connie Sun is Senior Vice President of Business & Corporate Development at Pharmaron. She is responsible for cross-functional business and corporate development, partnership alliance management and program management. Prior to joining Pharmaron, she has 16 years of drug discovery and development experience at biotech and pharma companies. She is author of 35 publications and inventor of 47 patents and is an inventor of Sutent®, which is currently marketed by Pfizer. She previously held positions as Head of Chemistry at Poniard Pharmaceuticals, Senior Director at AGY Therapeutics Inc. and Director of Chemistry at Pfizer (SUGEN).

Connie holds a Ph.D. in Medicinal Chemistry from University of North Carolina, Chapel Hill, North Carolina. Her postdoc training was at Parke-Davis, Warner-Lambert (later Pfizer), Ann Arbor, MI.

Tao He, PhD
Co-Founder & SVP, JOINN Biologics

Tao He is the co-founder of JOINN Biologics US Inc., a premier CDMO dedicated to biologics development and manufacturing. He has over 20+ years' experience in pharma/biotech (Novartis, Celera Genomics, Wyeth, and Pfizer) and is an expert in protein-based drug discovery and development. He commands in-depth knowledge and experience with managing biologics development programs and is widely recognized as an industry leader and senior subject matter expert in the field of protein analytics. Tao was a pioneer in establishing develop ability assessment for biologics development and was a key note speaker at Bioprocessing Summit. As a project lead, he led and supported multiple biologics programs from preclinical through IND filing. Tao received his Ph.D. from University of Maryland and coauthored over 25 peer reviewed publications and nine granted patent.

Jiangwen Majeti, PhD, MBA
Global Category Leader , Genentech

Jiangwen Majeti has over 15 years R&D experience in the biopharmaceutical industry. As a Global Category Leader, Jiangwen is responsible for developing and executing Roche's global outsourcing strategy in Biomarker and Companion Diagnostics for clinical development. Previously, Jiangwen served as Senior Director of Business Development at PPD, where she combined her business training and research experience to support preclinical outsourcing. Prior to this, Jiangwen was a Senior Scientist at Amgen Inc., where she successfully led research efforts in both small molecule and biologics drug discovery programs. Before Amgen, Jiangwen also worked as a Scientist at GPC Biotech and led the development of LeadCode© Technology to enable faster drug IND filing.

Mike (Yiding) Chen
Founder and CEO, AcroBio

Mike (Yiding) Chen previoiusly worked as application scientist and project manager at Life Technologies and Thermofisher. Mike Chen founded ACRO-Biosystems in 2010, a biotech company that is committed to providing high quality protein reagent products with unique protein labeling technologies, specially designed for antibody drug development. The company keeps focusing on timely addressing needs of customers from over 60 countries. Mike Chen has over 15 years experience in pharmaceutical and biotech industry, developed the first serum-free cell culture process for rabies vaccine production in China. He has led the company to market their products to over 60 countries.

Panel Discussion
Innovative Therapy in Oncology, What is Next?

Wenfeng Xu, PhD
VP of Research, Hengenix

Wenfeng Xu is currently the Vice President of Research at Hengenix Biotech, affiliated to Shanghai Henlius Biotech, a top biopharma company in China. Hengenix has a successful track record in moving multiple research leads into clinical stage with quality and speed, including the first biosimilar approval in China, 2 NDA filings and 27 IND approval in 9 years. Our goal is to accelerate the discovery and development of innovative biologics, and build a diversified and differentiated immuno-oncology portfolio.

Dr. Xu started his industrial career at ZymoGenetics in 1997, as part of the team to discover several cytokines and immune receptors (e.g. IL20, IL21, IL22, BAFF, IFN-lambda, TIGIT, B7H6, co-inventor of 37 issued US patents). He joined Novo Nordisk in 2008 as Director of Molecular Immunology, built a team to provide molecular technologies and antibody expertise for

target validation and trial support in the area of autoimmune and inflammatory diseases. Prior to joining Hengenix last year, he became Associate Director of BioAnalytical Sciences at Genentech in 2015, and his group focused on driving bioanalytical strategies and providing PK/ADA/biomarker assays for Cancer Immunotherapy clinical projects.

Wenfeng was the recipient of Genentech Development Sciences "the Power of We award" for cross-functional partnership and collaboration in 2017, ZymoGenetics "Eureka award" for outstanding scientific breakthrough in 2003, and Chinese Academy of Sciences "the First Place Science award" in 1998. He received his bachelor's degree in Biochemistry at Fudan University, Ph.D. in Molecular Biology at Chinese Academy of Sciences, and postdoctoral training at University of Washington in Seattle.

Jingrong Jean Cui, PhD
CSO, Turning Point Therapeutics

Jingrong Jean Cui is the Scientific Founder, Director, and Chief Scientific Officer at Turning Point Therapeutics (TP). Dr. Cui is an internationally renowned oncology drug designer with more than 20 years of experience in drug discovery and project management at major pharmaceutical and biotech companies. At TP, Dr. Cui has been focusing on addressing drug resistance issue in precision medicine, an urgent unmet medical need in oncology. Currently, TP's lead clinical compound TPX-0005 (Repotrectinib) is in Phase 1/2 clinical trial and two other pipeline projects are expected to enter clinical development in 2019. Prior to TP, Dr. Cui was Associate Fellow at Pfizer and she is the lead inventor for Pfizer's oncology drugs XalkoriTM (crizotinib) and LorbrenaTM (lorlatinib). Dr. Cui also designed Pfizer's clinical compound PF-04217903 for c-MET program and participated in development of oncology drug SUTENT.

Dr. Cui is the author of more than 60 scientific publications and patents. Among them, the patent for Crizotinib (US patent 7858643) won the 38th National Inventor of the Year Award in 2011. This highly prestigious award is selected by Intellectual Property Owners Association to recognize a high impact invention in U.S. Each year, only one patent across all industries is selected for this special award. Dr. Cui was a winner of the 2013 American Chemical Society's Heroes of Chemistry Award. She was the winner of the inaugural CABS K. Fong Award in Life Sciences in 2013. For her significant accomplishments at Pfizer, Dr. Cui received Pfizer's Worldwide Research and Development Achievement Awards in 2006 and 2012, and Innovation Award in 2011.

Dr. Cui obtained her Ph.D. in Organic Chemistry from The Ohio State University and her postdoctoral training at University of California, Berkeley. Dr. Cui received her B.S. and M.S. from the University of Science and Technology of China.

Mark Nevins, MBA, MS
VP of Business Development, Apexigen

Mark Nevins joined Apexigen near its founding and serves as Vice President, Business Development. Prior to joining Apexigen, Mr. Nevins served as Director, Business Development at Aradigm Corp., and at Abgenix, Inc. and held positions of increasing business development responsibility at G. D. Searle & Co, the pharmaceutical subsidiary of Monsanto Company.

Mr. Nevins has more than 35 years of pharmaceutical industry experience; nearly 20 of those years have been devoted to business development and licensing. He has negotiated license agreements and strategic alliances, managed research collaborations, and, while at Abgenix, he participated in the transformative strategic alliance with AstraZeneca for the development of antibodies against multiple oncology targets. Earlier in his career, he conducted drug discovery research for G. D. Searle & Co. Mr. Nevins holds a Master's Degree in Psychology from Central Michigan Universty and an MBA from Dominican UniversityBachelor of Science degree in Chemistry from Peking University.

Yanyan Zheng, PhD
Principle Scientist, Merck

Yanyan Zheng is currently a Principal Scientist in Discovery Oncology at Merck & Co. Inc., leading the tumor intrinsic targeting and translational pathology group. As a seasoned drug hunter, she is interested in bringing innovative therapeutics to patients with unmet medical need. Her expertise encompasses a broad range of processes in drug development, from target identification/validation, biologics discovery, to translational research. Dr. Zheng received her Ph.D. in Molecular Microbiology and Immunology, with a concurrent M.S. degree in Biostatistics, from University of Southern California. She conducted her Postdoctoral Fellowship training in Cancer Biology at Stanford University.

Tara Arvedson, PhD
Director of Research, Amgen

Tara Arvedson is a researcher and team leader in the Oncology Research department at Amgen. She received her Ph.D. at Caltech and was later a Damon Runyon Cancer Research Fellow at UC San Diego. Since being at Amgen she has led multiple programs targeting benign and malignant hematology using both large and small molecules. These programs have progressed from discovery stage to the clinic.

Peiwen Yu, PhD
VP of Discovery Biology, Exelixis

Peiwen Yu currently serves as Vice President, Discovery Biology at Exelixis, Inc. Dr. Yu has been an Exelixis veteran for more than 17 years joining the company in 2001 with a successful track record of her work on cabozantinib and cobimetinib. Dr. Yu began her Exelixis career as a drug discovery Scientist, rose through the ranks, and extended her work experience from discovery to development. During her Exelixis tenure in 2012-2014, she was Senior Director of Medical Affairs and primarily managed the IST & CTEP trials, the compassionate use and single patient IND for cabozantinib, and several preclinical partnerships. From 2015-2017 during a brief break from Exelixis, Dr. Yu joined OBI Pharma as Vice President of Translational Research. At OBI, she established the Translational Medicine department, led the oncology vaccine pipeline, implemented a management matrix to oversee the in-house research projects, supported clinical trial design and data analysis, and led scientific due diligence efforts to support external licensing deals and partnerships. In 2017 she returned to Exelixis where she rebuilt the discovery biology department which includes the compound repository, high-throughput screening, tumor biology, and pharmacology groups.

Although the majority of her career was spent at Exelixis, Dr. Yu started her career in industry at Rigel, Inc., and Hoffman-La Roche where she finished her post-doctoral research fellowships. The combination of that work provided Dr. Yu with more than 20 years of extensive experience in oncology drug discovery and development, immuno-oncology, inflammation, translational medicine, and medical affairs.

Dr. Yu received her Ph.D. in Immunology/Pathobiological Sciences from University of Wisconsin-Madison, BS and MS form National Taiwan University, and studied EMBA at NCCU 2016-1017. She also severed as a president of the Chinese Bioscience Association in 2012; and a board director of TFGHAA-NC in 2010-2011.

Cheni Kwok, PhD, CLP
Managing Partner and Founder, Linear Dreams

Cheni Kwok is a senior biopharmaceutical executive with broad operational expertise who has executed over 150 transactions including M&A, strategic partnerships, licensing, divestitures, spin-offs and project financing. Dr.Kwok is the Managing Partner and Founder of Linear Dreams LLC, a management consultancy for the life sciences industry. The firm's engagements include a broad range of business and corporate development activities including managing business development teams, product and technology licensing, search & evaluation of products and technology platforms, merger & acquisitions, corporate strategy, portfolio planning, market and competitive intelligence, due diligence support for financing as well as valuation services for 45 biopharmaceuticals companies, contract research & non-profit organizations, research institutes and investors in USA, Europe, China, Taiwan and Singapore.

As Senior Vice President, Corporate Development at Poniard Pharmaceuticals Inc., Dr. Kwok established corporate and business development, strategic and commercial planning, new product planning, competitive intelligence and forecasting functions. Previously, she was Director of Business Development at Celera Genomics Inc., where she led the business development efforts for Celera's small molecule therapeutics, including the divestiture of the oncology pipeline (including Imbruvica® (ibrutinib)) to Pharmacyclics Inc. (now an AbbVie Company). Dr. Kwok held business development positions of increasing responsibility at Exelixis Inc., where she initiated multiple partnerships and served as the alliance manager for the GlaxoSmithKline PLC (GSK) collaboration. Prior to joining Exelixis Inc., she held various research management, technology assessment and alliance management roles at SmithKline Beecham PLC (now GSK).

Dr. Kwok received a bachelor's degree with first class honors in biotechnology from the Imperial College of Science, Technology and Medicine, University of London, UK, a Ph.D. in human molecular genetics from the University of Cambridge, UK and has earned the Certified Licensing Professional (CLP) credential. At present, Dr. Kwok is serving as the Board of Directors of Chinese-American Biopharmaceutical Society (CABS) and serves on the Standards, Admissions & Recertification committee of Certified Licensing Professionals, Inc..

2018 – 2019 CABS Activities

CABS Successfully Hosted "2019 Investor Forum" During JPM

San Francisco, CA (January 9th, 2019) – The 2019 CABS Investor Forum, co-organized by CABS and Morrison & Foerster LLP, was successfully held on January 9th of 2019 in conjunction with the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California. The forum featured two panel discussions among legal experts, investors, and company executives on topics of keen interest to the life sciences community. Dr. Yang Tian, President-elect of CABS welcomed over 160 attendees in the opening remarks.

The first panel discussion, moderated by Dr. Janet Xiao, Co-Chair of Global Life Sciences Group of Morrison & Foerster LLP, focused on the policy trends, strategies, opportunities and challenges of investment in bio-pharmaceutical industry.

Last summer, legislation was passed to expand the jurisdiction of the Committee on Foreign Investment in the US (known as CFIUS). In the past November, a new CFIUS "Pilot Program" became effective and allows CFIUS to conduct national security review of minority investments by foreign entities on critical technologies. Biotechnology is one of the 27 industry fields included in the Pilot Program. Our panelists engaged in an extremely informative and interactive discussion on this very timely topic. Mr. Benkert, who has significant experience in overseeing CFIUS cases, and in numerous cases have represented Department of Defense in CFIUS deliberations, shared

with the audience his insights on CFIUS issues and provided practical tips to investors and companies. Other panelists shared their views and strategies on their potential investment decisions under the new CIFUS regulation.

Dr. Wendy Pan, Partner of Sidley Austin LLP, moderated the second panel including the following experts: Jin Wang, PhD, Founding Partner of Manhattan Capital Group and Venture Partner of Puhua Capital, Mark Noguchi, MBA, Independent Advisor and Former Global Head at Roche Partnering, Wei Cheng, MBA, Venture Partner of Z-Park Fund and JoLee Li, PhD, Managing Director at Lang Sheng Investment Group Co., Ltd. This panel discussion started with discussion about the criteria of pharmaceutical investments from the perspectives of the investors. Pharmaceutical industry is very competitive and drug discovery is a tough journey. Companies should be always aware of how to distinguish themselves and think about the road down ahead. The topics also included how to grow an invested company, how to increase the value of the company and how to have a successful IPO. Panelists used some successful investment examples to that active investment, efficient workflow and communications are the keys to have a win-win outcome.

The panel discussions were followed by interactive one-on-one and small group discussions with panel experts and networking among attendees. Lunch and refreshments were generously provided by Morrison & Foerster LLP.

Membership (MEM)

Co-Chairs
Han Zhang and Wenming Zhang

The mission of the Membership Committee is to help build the CABS membership and support base. Our key objectives are:

- Support all major CABS events registration and check-in process
- Recruit and train CABS volunteers
- Support our outreach to new members

Public Relations & Communications (PRC)

Co-Chairs
Chenling Xiong and Hesong Han

The CABS Public Relations & Communications (PRC) Committee leads and builds communication channels between CABS, its members and the local biotech community. We are responsible for keeping the CABS website up-to-date, posting events and announcements. Our weekly newsletters promote our upcoming events, highlight past events and provide information about new career opportunities. For CABS annual BioPacific Conference, the PRC takes the lead to prepare a high-quality conference brochure for event attendees, which is one of the highlights of the conference.

Alliance Management (AMC)

Co-Chairs
Xu Chen and Frank Hu

The Alliance Management Committee is the core team of CABS in forging alliance with partners and sponsors and bringing the best value. The committee is in charge of recruiting and working with our year-round partners and sponsors and provide the company branding, the service and product promotion, the talent recruitment, the project collaboration, and the networking and partnership opportunities. We not only keep looking for new partners and sponsors but also keep the connection with previous ones to culture a long-term relationship. Our partners and sponsors come from a variety of communities, which includes but not limited to China and US pharmaceutical companies, CRO companies, business parks, law firms, and venture capital investment firms. In addition to building partner and sponsor relationships, we together with other CABS committees build a variety of flagship events across the year to provide the best valuable services. Below are some highlight accomplishment and events:

RAMED China Medical Device Regulatory Forum

Burlingame, CA (July 28th, 2018)- RAMED China Medical Device Regulatory Forum has been successfully organized by Chinese-American BioPharmaeutical Society (CABS) and RAMED. The forum aims to help the companies and the scientific research institutions in the US to understand the China medical device market characteristics and the CNDA regulatory requirements. We were honored to have welcomed more than over 60 attendees and with various backgrounds, including R&D, regulatory affairs, clinical research, marketing, etc. The forum was a real success and has achieved a very good response from the audience who attended the forum.

Speakers included: Yongheng Chang,Chief Advisor of RAMED; Ellen Jiang, Founder of RAMED; Christine Jiang, Co-founder & Regulatory Affairs Director; Jane Shen, Senior Consultant of RAMED.

New Opportunities in China after CFDA joined ICH

Burlingame, CA (August 27, 2018) – CABS workshop "New Opportunities in China after CFDA joined ICH" was successfully held on August 25, 2018, at Hanhai Biolabs in Burlingame, California. The workshop featured four presentations and attracted more than 160 attendees from life science related industries including biopharmaceutical companies, academic institutions, and venture capital firms. Workshop topics covered drug development in the era of ICH, legal considerations for company establishment in the US and China, structures for collaboration and licensing agreement, and the introduction of Qidong's investment environment for biopharmaceutical industries.

Dr. Dan Zhang, Executive Chairman at Fountain Medical, introduced the implications of China joining the ICH. Particularly, he discussed its effects on global drug development plans and business models in the era of ICH.

Chuck Comey, Partner at Morrison & Foerster LLP, shared his expertise in legal considerations for company establishment in the US and China. Specifically, Mr. Comey mentioned about the recent assigned FIRRMA by the US President and its potential impacts on CFIUS and foreign investors.

Dr. Scott Carter, Of Counsel at Morrison & Foerster LLP, introduced the legal considerations for cross-border licensing deals and reviewed some recent deals in the pharmaceutical industry. Particularly, he mentioned new opportunities to develop biosimilar products in China.

Mr. Kangli Wang, the Executive Deputy Mayor of Qidong City, and his accompanying delegation from Qidong City, also attended this workshop and introduced investment environment in Qidong City. Qidong is a vibrant coastal city with strategic plans and distinctive qualities. It has strong growth momentum, strategic location, and well-linked transport infrastructure, making it a promising city with great potential in life science industry. Right now Qidong is opening her arms and welcoming all entrepreneurs and returnees to join forces to build it into one of the top life science innovation hubs, the healthcare industry bases, and the riverside eco-friendly communities around the globe.

Preclinical and Early Phase Drug Development

Burlingame, CA (December 11th, 2018) – CABS workshop "Preclinical and Early Phase Development of Biologics and Small Molecules" sponsored by Frontage Laboratories, Inc., was successfully held on December 11th, 2018 at DoubleTree Hotel in Burlingame, California. The workshop featured four presentations by leading experts in areas of preclinical and early-stage development of biologics and small molecule

therapeutics and a lively panel discussion on hot topics and emerging trends in biologics and small molecule drug development. Around one hundred attendees well received the workshop from life science-related industries including life science technology companies, biopharmaceutical companies, academic institutions, and investment firms, Speakers included: Dr. Hugh M. Davis, PhD, Chief Business Officer, Frontage; Dr. Steven Chamow, PhD, Vice President of Development at Aridis Pharmaceuticals. Inc.; Dr. Yuanchao (Derek) Zhang, PhD, President, Alavanda Regulatory & Drug Development Consulting, Inc.; Dr. Mark T. Marino, MD, Chief Medical Officer at Imugene Ltd.

Intellectual Property Strategy for Startups: Grow and Exit

Burligame, CA (April 27, 2019) CABS and Finnegan, Henderson, Farabow, Garrett & Dunner, LLP successfully hosted the biopharmaceutical intellectual property seminar "Intellectual Property Strategy for Startups: Grow and Exit," in Burlingame, CA, on April 27, 2019. Hanhai BioLabs generously provided the venue for the seminar, which featured two presentations and a panel discussion by intellectual property ("IP") attorneys who are highly experienced in patent protection, enforcement, and licensing.

The first presentation, by IP attorney Mr. Michael Liu Su of Finnegan, focused on "Recent Developments on Hot Technologies from an IP Perspective." Specifically, Mr. Su discussed the IP issues of CRISPR and CAR-T—two rapidly developing new technologies. Mr. Su discussed, for example, how companies and research institutes have been patenting these technologies and enforcing the patents.

The second presentation, by IP attorney Dr. Yieyie Yang of Finnegan, covered "Due Diligence for Startups." Dr. Yang discussed how to conduct a thorough freedom-to-operate analysis to understand the IP landscape of the field in which a startup operates and the available options management has when facing patents the startup may infringe, so as to minimize risks and satisfy investors.

The panel discussion featured attorneys Dr. Bing Hai of Bristol Myers Squibb, Mr. L. Gavin Liu of Latham and Watkins LLP, and Dr. Yang from Finnegan, moderated by Mr. Su. The panelists covered "Best Practices for Startups Needing to Develop Effective and Attractive IP Portfolios." Specifically, they discussed tips for building a startup's own patent portfolio, for obtaining and maintaining a strong in-licensed portfolio, and for successfully out-licensing these portfolios. The audience participated extensively, asking a variety of questions relating to these tips.

Afterwards, the presenters, panelists, and audience stayed to discuss IP issues and exchange ideas.


Formulation
Polymorph/salt form
Manufacturing proc
Dosing
Biomarkers
Device


A Gateway Linking Life Sciences Professionals and Organizations Around the World


Panel Discussion:
Best Practices for Startups Needing to Develop Effective and Attractive IP Portfolios


A Gateway Linking Life Sciences Professionals and Organizations Around the World
CABS

Science & Technology Committee (STC)

Co-Chairs
Ken Zhang and Xiang Yi

The CABS Science & Technology Committee fosters scientific exchanges in the life science industry. Each year, the committee organizes a series of seminars to discuss the current trends and cutting edge technologies in life sciences. Members of CABS not only benefit through the seminars but also have the opportunity to interact directly with the speakers who are usually veterans, well-known scholars, or entrepreneurs. Also, the seminar series provides members the opportunity to connect with other professionals with diverse areas of specialization, which could lead to unexpected insights.

Therapeutic Antibody Technology and Development

Burlingame, CA (November 3rd, 2018) – CABS workshop "Therapeutic Antibody Technology and Development" was successfully held on November 3rd, 2018 at Hanhai Biolabs in Burlingame, California. The workshop featured six presentations and attracted more than 120 attendees from life science related industries including biopharmaceutical companies, academic institutions, and venture capital firms.

Dr. Mason Lu, Founder and CEO of MedAbome, Inc., provided a comprehensive review on the basic science of antibody molecules and the cutting-edge technologies for the development of therapeutic antibodies. Particularly, he focused on the application of AID, APOBEC3 deaminases and phage display technology in antibody generation and maturation in the field of biopharmaceutical research and development.

Dr. Chun-Nan Chen, CEO & CSO of Single Cell Technology, Inc., introduced a unique and high throughput platform for versatile antibody discovery: Single Cell Technology. During his talk, he shared his technical expertise in antibody discovery and case studies of antibody discovery campaigns.

Mr. Yonglei Shang, Head of Antibody Therapeutics, Amberstone Biosciences, LLC., shared his expertise of main technologies of antibody discovery in industry. In his talk, he discussed challenges of current methods and introduced emerging technologies such as deep sequencing and microfluidics/microchamber that have been integrated for enhancing, high throughput and optimization of antibody discovery.

Dr. Qiang Liu, Director of Antibody Engineering at Twist Bioscience, shared his expertise in the discovery of bispecific antibodies: from the basic science of bispecific antibodies to the success applications of two approved bispecific antibody drugs: Amgen's Blinatumomab and Roche's HEMLIBRA®.

Dr. Naibo Yang, SVP & COO of GenoImmune Therapeutics Inc (A BGI company), introduced the unique single-domain antibodies from Camelids and Sharks. Specifically, he talked about the special properties of these antibodies and their therapeutic and diagnostic application potential.

Ms. Haichun Huang, CSO of NovaRock Biotherapeutics, was previously Director of Hybridoma Research at BMS/Mederax. She is the co-inventor of 133 antibody research and development patents and co-inventor of Nivolumab (anti-PD1 mAb) and Ofatumumab (anti-CD20 mAb). Her talk covered her personal story in the discovery and development of therapeutic antibodies.

Small Molecule Drug Discovery

Burlingame, CA (February 16th, 2019) CABS workshop "Small Molecule Drug Discovery" was successfully held at Hanhai Biolabs. CABS Science and Technology Committee led the workshop sponsored by ChemShuttle. Four leading experts presented their current research strategies and new approaches on small molecule discovery and development. Topics covered molecule modeling and rational design, medicinal chemistry, API manufacturing through enzyme engineering approach, CD73 checkpoint inhibitor, and HCV drug development case study. More than one hundred attendees from academia and life science industry attended the workshop.

Dr. Devleena Shivakumar, Senior Scientist in the Structural Chemistry Department at Gilead Sciences Inc, talked about the computational modeling application in small molecule drug discovery. She gave an introduction about the perspectives and process for the application of the design tools to identify potent compounds. Then, Dr. Shivakumar covered her computational studies in the lead optimization of potent macrocyclic Cyclophilin inhibitors for HCV treatment, which simplified the

molecular complexity while maintained the potency. Dr. Shivakumar also touched on the free energy calculation technology (FEP+) to predict the IC50 which generated good correlation with the observed potency for the project.

Dr. Jim Lalonde, Senior Vice President of Research and Development at Codexis, started his talk by highlighting 2018 Nobel Laureate Francis Arnold and her pioneering work in directed evolution to engineer enzymes. Jim then introduced Codexis's platform technology CodeEvolver and how it harnessed the power of evolution to deliver high-performing enzymes in a wide array of applications. He elaborated eight enzyme classes ranging from reductase, transaminase, oxidase, acylase, to glycosylase, and how each of them was successfully engineered at Codexis and delivered to the pharmaceuticals to improve API manufacturing processes.

Dr. Brandon Rosen, Senior Scientist of the Department of Medicinal Chemistry at Arcus Biosciences, gave a talk about Arcus's approach to improve the immune response in the tumor micro-environment (TME) by identification of the novel checkpoint inhibitor targeting CD73 that blocks the generation of extracellular adenosine in tumors. Dr. Rosen rationalized the targets mechanism biology, molecule design from the protein structure and further discussed the medicinal chemistry work to optimize the compound potency and physical properties.

Dr. John O. Link is currently Vice President, Medicinal Chemistry at Gilead Sciences. Dr. Link received his Ph.D. in Chemistry under the direction of EJ Corey at Harvard University in 1992. From 1992-1996 John worked at Syntex/Roche Palo Alto and from 1996-2006 Dr. Link worked on protease inhibitors at Celera (South San Francisco) in inflammation and antiviral areas with three compounds entering clinical trials. John joined Gilead in 2006. Since then, either under his direct leadership or under the leadership of this group, Gilead moved three small molecule HCV inhibitors from discovery to FDA approved drugs, including two HCV NS5A inhibitors and one HCV NS3 protease inhibitor. Those molecules are now part of three HCV therapies, including Harvoni, Epclusa and Vosevi. His presentation was on the discovery of two HCV NS5A inhibitors, and their pre-clinical and clinical data. The evolution from 1st generation HCV NS5A inhibitor that is effective mainly on HCV genotype a to 2nd generation inhibitor that is pan-genotypic was also discussed. Compared with old HCV standard care which is PEG-IFN and Ribavirin that shows a big difference in efficacy between clinical trials and real world patients, fixed-dose combination therapy of HCV that are developed at Gilead, results in high cure rate both in clinical trials and in real world patients.

CABS CAR-T and Cell Therapy Symposium

Burlingame, CA (April 6th, 2019) – CABS CAR-T and Cell Therapy Symposium was successfully held at Hanhai Biolabs in Burlingame, California. The symposium featured five presentations and attracted more than 150 attendees from life science industries including bio-pharmaceutical companies, academic institutions and venture capital firms. The leading experts shared their point of view regarding the latest research and development in T cell gene editing and engineering technology, PK/PD of CAR-T therapy and the next T cell immunotherapy in oncology. This symposium was led by CABS Science and Technology committee, co-chaired by Dr. Ken Zhang and Dr. Xiang Yi.

Dr. Ling-Jie Kong, Vice President, Technology Development, Applied StemCell, Inc., introduced the CAR-T therapy background, therapeutic benefits and challenges for CAR-T production and manufacture. He presented Applied StemCell's technology on gene editing in primary T cell and the TARGATT platform on iPSc-based allogeneic T cell therapy.

Jane Liu, Product Manager, ACROBiosystems, emphasized the

importance of evaluating CAR expression as an essential step in CAR-T cells production. She introduced the flow-chart of the CAR-T production process and further detailed the comparison of different reagents and methods for the detection of CAR expression with case studies. At the end, she discussed quality assays, quantitative measurement, lot consistency and other CAR-T product QA perspectives.

Dr. Jingyi Xiang, Director of Scientific Alliances, Eureka Therapeutics, Inc., discussed Eureka's proprietary ARTEMIS™ antibody TCR (AbTCR) T-cell receptor platform, which was designed to create potentially safer and more effective T-cell therapies. Dr. Xiang presented Eureka's preclinical and clinical studies of its CAR-T therapy in liquid malignancies and solid tumors.

Dr. James Kalabus, Principle Scientist, Clinical Pharmacology, Modeling & Simulation at Amgen introduced Chimeric Antigen Receptor (CAR)-T background and the design. He addressed the challenges of pharmacokinetics and pharmacodynamics studies of CAR-Ts. He shared his expertise in dose-exposure and exposure-response relationships associated with CAR-T therapy, and some of the primary pharmacodynamic and safety concerns related to administration of CAR-Ts.

Dr. Barbra Sasu, Chief Scientific Officer at Allogene, provided a comprehensive review on autologous CAR-T therapy followed by the introduction of the advantages of allogeneic CAR-T therapy. She highlighted the clinical data available to date, and the overall research and development strategy for a pipeline of allogeneic CAR-T therapies across a range of hematological and solid tumor indications.

International Collaboration (ICC)

Co-Chairs
Wenfeng Xu and Qiang Gan

The CABS International Collaboration Committee (ICC) strives to promote international collaborations with various life sciences organizations and serves as a bridge that connects our members to life sciences communities in the Pacific Rim countries. In the past year, we have arranged many events to help both American and Chinese companies seeking for proper scientific and investment collaboration locally and globally.

Business & Career Development (BCD)

Co-Chairs
Liping Meng and Anthony Hsiao

Huijun Zhou, E-Club Chair, iDNA
Jenen Tan, Toast Master President, IQVIA
Joe Zhang, CAN Director, Stanford University

Our mission:

- *To serve the business and career development needs of our members and the San Francisco Bay Area life sciences community*
- *To provide our members with interactive, informative platforms and networks to launch, to transition, or to advance their careers in the life sciences industry*
- *To enable our sponsors to effectively recruit talent, management team, and innovative projects*

Artificial Intelligence and Precision Medicine

Burlingame, CA (November 10th, 2018) – The CABS workshop "Artificial Intelligence and Precision Medicine" was successfully held on November 10th, 2018 at Hanhai Biolabs by the Entrepreneurship Club. The workshop featured six presentations followed with a panel discussion and attracted more than 150 attendees with very diverse backgrounds, including biotech, pharma, academia, investment, etc.

Dr. Alex Franzusoff, CEO of PACT Pharma, has shared their theory about how to develop the next generation synthetic tumor-infiltrating lymphocytes to treat cancer patients. The company believes that it is critical to unleash a tsunami of T cells that recognize and kill cancer cells displaying patient-specific neo-epitopes. To achieve this goal, they will use the machine learning approach to identify common neo-epitopes and then target them. "It is crucial to focus on the trunk instead of the leaves and branches" Commented Dr. Franzusoff.

Dr. Prasun Mishra, CEO and Founder of Agility Pharma, provided a comprehensive review of the basics of artificial intelligence and how it has been applied in various areas of the healthcare and pharmaceutical industry. Particularly, Dr. Mishra mentioned that artificial intelligence is going to be the future. At present, it is increasingly playing an irreplaceable role in advancing the drug discovery and development process.

Dr. Michael Januszyk, Senior Research Scientist of NuMedii, shared their approach to push forward drug discovery through the use of artificial intelligence, big data, and system biology. Specifically, the AIDD technology, NuMedii's core platform, employs deep learnings of human biology consisting of hundreds of millions of structured molecular, pharmacological and clinical data points that the company has curated and harmonized. They further couple these data with proprietary machine learning and network-based algorithms to discover and advance precise, effective new drug candidates, as well as biomarkers predictive of efficacy for subsets of patients, in a broad spectrum of therapeutic areas including orphan diseases like IPF.

Dr. Thomas Wechsler, Senior Director of Sangamo, discussed how to utilize the zinc finger nuclease technology to recognize and bind to specific DNA sequences and thus edit them precisely and efficiently. He also shared their latest developments in clinical trials, including the treatment of MPS I, MPS II and hemophilia B.

Dr. Rachel Haurwitz, CEO of Caribou Biosciences, went into details about how to use CRISPR-Cas system to edit genes and promote applications in industries, including therapeutics, agricultural biotechnology, biological research, etc.
Mr. Andre Watson, CEO of Ligandal, has revealed the secret to their technology. The company uses the power of ligands - molecules that bind with specific other molecules - as well as a breakthrough nanomedicine platform to target the precise molecular 'zip codes' (receptors) of cells and their nuclei. Thus, their technology has no inherent immunogenicity or toxicity, enables precise engineering and flexible payloads, and can time-release the delivery of new characteristics into the correct organelle of the cell.

Social Life (SLC)

Co-Chairs
Sihong Zhou and Michael Xie

The Social Life Committee (SLC) is dedicated to serving our members with high quality indoor and outdoor activities. Within the CABS community, SLC intends to provide the opportunity to make the connection, build the relationship and enhance the interaction; to enrich and improve life quality by sharing knowledge, organizing fun events, and co-creating memorable
experience. The key objectives of CABS Social Life Committee are:

- To serve our CABS members through hosting seminar & talks, and organizing social activities.
- To provide networking and social interaction platform for CABS family.
- Support all major CABS events registration and check-in process
- Recruit and train CABS volunteers
- Support our outreach to new members
- To create an opportunity for friendship and professional development.
- To promote a healthy and positive lifestyle for our CABS community.

CABS 2018 Annual Summer BBQ

CABS 2018 Annual Summer BBQ was successfully held at the Twin Pines Park in Belmont on August 19. More than 200 CABS members, families, and friends attended this annual event.

Summer BBQ served as a relaxing social networking platform for CABS members and friends. Other than delicious food, CABS summer BBQ provided our members and friends an opportunity to exchange inspiring ideas for drug development, plan future business, meet potential investors/partners/customers/employers/employees, explore business development opportunity in a relaxing environment.

2019 CABS Chinese New Year Gala

Foster City, CA (February 2, 2019) - CABS 2019 Chinese New Year Celebration successfully held at the Foster City Recreation Center on Feb 2, 2019. More than 270 CABS members, families, and friends attended this fun event, and everyone enjoyed the authentic Chinese food, fun activities and the performances.

The 1st CABS Ping Pong Tournament

San Carlos, CA (Mar 3rd, 2019)-The first Ping Pong Tournament was successfully held in PongPlanet Table Tennis Club. This fun and exciting event attracted more than 25 CABS members.

After rounds of competitive games, Dong Su and Xiang Yi became the champion for Men's and Women's Singles respectively. The event provides a platform for CABS members to exercise, stay healthy, interact with each other and build friendship.


ChemPartner
Dedicated to LifeScience
Capabilities
Hybridoma
Engineering
Maturation
Phage display
Assay development
Reagent generation
Target specific binding
Neutralization
Epitope diversity
Recombinant protein production

BIOSYSTEMS Acro | Recombinant Proteins for Biopharma Industry

Human CD20 Full Length Protein

- HEK293 Cells & Insect Cells Expression
- Complete Conformation
- High Bioactivity



FGL1 : A Novel Immune Inhibitor of LAG-3

- HEK293 expressed
- More species and tags to choose
- Avitag™ Biotin-labeled available

NEW PRODUCT LAUNCH



MABSOL®Biotinylated Proteins

- Closest to Natural Conformation and Modification
- High Bioactivity & Detection Sensitivity
- High Batch-to-Batch Consistency



Suitable for Detection of CAR Expression

50% OFF FOR NEW CUSTOMER
CAR-T Target Proteins





>>>Flow cytometry validated and protocol offered<<<

ACROBiosystems is a leading manufacturer of recombinant proteins. We provide high-quality protein reagents and technical support to the biopharma community. Our catalog includes biotinylated proteins, immune checkpoint proteins, Fc receptor proteins, CAR-T cell therapy targets, biosimilar drug targets, anti-idiotypic antibodies, and quantitative analysis of mAb in serum.

Thinking innovation. Delivering solutions.

Hanhai Silicon Valley is the first Sino-U.S. high tech business incubator in Silicon Valley.

We are committed to be the leader in life sciences. We establish the state-of-the-art startup ecosystem to empower innovators around the world to build sustainable business and to solve the most challenging problems in life sciences.

- Office Spaces
- Mentors & Advisors
- Events & Networking
- Funding Opportunities

DISCOVER. ENGAGE. COLLABRATE.

YOUR *One-stop service provider & Trusted global partner.*

HANHAI | INVESTMENT™

GET IN TOUCH!

650-239-9727
info@hanhaiinvestment.com
1633 Old Bayshore Highway, Suite 280, Burlingame, CA 94010



MOFO LIFE SCIENCES

Our newest blog shares timely legal and business insights and in-depth analyses on trends and the complex technologies at the heart of the global pharmaceutical, biotechnology, diagnostics, medical devices, digital health, and AgTech fields.

Get the latest legal and business insights impacting the global life sciences community.

lifesciences.mofo.com

MORRISON FOERSTER

WuXi AppTec Group

药明康德集团
WuXi AppTec Group

Our Vision

"Every drug can be made and every disease can be treated" through building the open-access platform with the most comprehensive capabilities and technologies in the global healthcare industry.

Company Overview

WuXi AppTec Group is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with global operations. As an innovation-driven and customer-focused platform, WuXi AppTec Group provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule drug R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, drug R&D and medical device testing, genomics and data platform, in-vitro and clinical diagnostics, WuXi platform is enabling more than 3,500 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated."

30+	23,000+	18,000+	3,500+
Global Sites	Global Employees	Scientists	Collaborative Partners

Enabling Platform

Small Molecule Drug R&D and Manufacturing

One of the world's largest and most experienced chemistry R&D team, one of the world's largest Contract Development and Manufacturing Organization (CDMO) of small molecule drugs, the end to end enabling platform for small molecule drug design, synthesis, research, testing, and manufacturing.

Cell Therapy and Gene Therapy

Accelerating and transforming development, manufacturing & commercialization of cell, gene, and other advanced therapies through our enabling technologies and platforms and our integrated testing to the benefit of patients worldwide.

Drug R&D and Medical Device Testing

We provide a world class, globally integrated testing solution for drug development and medical device innovation. We enable scientists to transform ideas into the best healthcare products, accelerate the race from bench to bedside, and ultimately improve human life.

WuXi AppTec
(Stock code: 603259.SH/2359.HK)

Biologics R&D and Manufacturing

An open-access biologics technology platform in the world, offering end-to-end solutions to accelerate and transform how biologics are discovered, developed and manufactured, so as to bring more much-needed treatments to patients globally.

WuXi Biologics
(Stock code: 2269.HK)

Genomics and Data Platform

An emerging genomics data enabling platform, leading global population genomics, precision medicine, diagnostics and wellness initiatives by using the genome to improve human health around the world.

WuXi NextCODE

In-vitro and Clinical Diagnostics

We enable precision medicine through a unique dual-enabling platform for in-vitro diagnostic service and product innovation. Our revolutionary platform integrates multi-dimensional, multi-omics medical data to generate deep clinical insights, and pioneer innovation by building a novel eco-system for healthcare industry. We strive to ensure every disease can be precisely diagnosed, and everyone can enjoy a better and healthier life.

WuXi Diagnostics

Henlius is a leading biopharmaceutical company in China with the vision to offer high-quality, affordable and innovative drugs for patients worldwide. Since its inception in 2010, with the R&D footprints in Shanghai, Taipei, China and California, USA, Henlius has established, and continues to expand, a comprehensive product pipeline of both biosimilars and bio-innovative drugs, for the treatment of tumors and autoimmune diseases

- HLX02(Trastuzumab) → Breast Cancer (BC), Gastric Cancer (GC)
- HLX03(Adalimumab) → Rheumatoid Arthritis (RA), Psoriasis (PS)
- HLX04(Bevacizumab Biosimilar) → metastatic Non-Small-Cell Lung Cancer (mNSCLC), metastatic Colorectal Cancer (mCRC)
- HLX05(Cetuximab Biosimilar) → Squamous Cell Carcinoma of The Head and Neck (SCCHN), metastatic Colorectal Cancer (mCRC)
- HLX12(Ramucirumab Biosimilar) → Advanced Gastric Cancer and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer (NSCLC), Metastatic Colorectal Cancer (mCRC)

Bio-Innovative

- HLX01*(Anti-CD20) → Rheumatoid Arthritis (RA)
- HLX04*(Anti-VEGF) → wet Age-Related Macular Degeneration (wAMD), Diabetic Retinopathy(DR)
- HLX06(Anti-VEGFR2), HLX07(Anti-EGFR), HLX10(Anti-PD-1), HLX20(Anti-PD-L1) → Solid Tumors
- HLX22(Anti-Her2) → Breast Cancer(BC), Gastric Cancer(GC)

Combo Therapy

- HLX10(Anti-PD-1) +HLX04(Anti-VEGF) → Solid Tumors
- HLX10(Anti-PD-1) +HLX07(Anti-EGFR) → Squamous Cell Carcinoma of The Head and Neck (SCCHN)

*Considered a bio-innovative product as the reference drug has not been approved for the relevant indication yet in China.

Shanghai Henlius Biotech, Inc.
Add: 9/F, Innov Tower, 1801 Hongmei Road, Shanghai, 200233, China
Web: www.henlius.com

JOINN Biologics

YOUR TRUST CDMO

JOINN Biologics US Inc. (JOINN Bio) is a Bay Area California-based company that is committed to the advancement of biopharmaceutics through its premier contract manufacturing and development services for biologics and advanced therapies. JOINN Bio provides a complete range of services from early development to clinical manufacturing to our clients in a global scale. Our core capabilities include:

- **Molecular/Developability Assessment**
- **Non-GMP protein expression & purification**
- **Cell line development**
- **Upstream and downstream process development**
- **Analytical and formulation development**
- **cGMP clinical trial materials production**
- **Commercial scale cGMP manufacturing**
- **Documentation and reporting to support regulatory filings**

JOINN Bio is part of the JOINN family who has over two-decades of successful track records supporting drug discovery and development from preclinical to clinical and commercial stages. Our experienced team works closely with our partners and clients to further accelerate the development of high-quality medicine and deliver long-lasting value to the biopharmaceutical industry. Please contact us at info@joinnbio.com or www.joinnbio.com for your biopharmaceutical development and manufacturing needs.

昭衍 JOINN

WWW.JOINNBIO.COM **WWW.JOINN-LAB.COM**

AbVision THERAPEUTICS

Harness the Nature Power of Immunity

Therapeutic Antibody

SpeedyAb™ technology platform provides high - throughput features of antibody screening for obtaining the therapeutic leads with high affinity and broad diversity.

Vaccine

ImmunoBuster™ technology platform develops one-shot vaccines with strong immunogenicity for prophylactic and therapeutic treatment without additional boost.

Cell therapy

ProKill™ technology platform enables low frequency of tumor-specific T cells to effectively destroy tumors by enhancing the functionality of effector cells and tumor recognition.

408-493-1822 | info@abvisioninc.com| http://abvisioninc.com
155 S Milpitas Blvd, Milpitas, CA 95035, USA

Bellen
Your premier source for heterocycles

Bellen Chemistry Co., Ltd. is a leading CRO and CDMO company in China. Chemistry is a premier provider of a variety of heterocycles with focuses on the design and development of novel molecules, and intermediates for the chemical and pharmaceutical industry. We have developed large scale synthesis for many heterocycles. Bellen also does process research manufacturing, custom synthesis, route scouting and medicinal chemistry, and process development FTE, to help customers reduce development risk and lower their cost for chemicals and the customer specific process development.Currently, Bellen Chemistry has a strong R&D team with a talent pool of 200+ trained scientists. We have excellent track records, delivering unrivalled chemical innovation to our customers worldwide.



8000 Jarvis Ave. Suite208, Newark, CA 94560
charles.chen@bellenchem.com
1-650-504-8848

BIOBASE®

BIOBASE LLC is the subsidiary of BIOBASE Group, founded in 2016,located in Fremont, CA with an area of 2,000 square meters.

BIOBASE LLC serves as Incubator to introduce talents and biotechnology companies of Silicon Valley, and strength connection and cooperation between US and China in Biotechnology area.

BIOBASE Group specialize in manufacturing high quality scientific instruments, IVD instruments and reagents, serving the laboratories, clinics and hospitals in U.S.

Address: 3231 Osgood Common, Fremont, CA 94539
Tel: +1 650 450 6852
Email: sales1_usa@biobase.com

Visit www.biobaseglobal.com to learn more details about our products.

MabPlex

MabPlex is a proud Silver Sponsor of CABS 2019

mabplexinc.com

Alliance and Promotional Partners

CABS MEMBERSHIP

CABS Membership Demographics

Our membership consists of life science professionals from a broad range of experience levels. A large percentage of our members hold senior or executive positions in the industry, and we are proud to have numerous entrepreneurs who have successfully started and sold life science companies in our pedigree. In addition, we continue to attract new talent from the local academic institutions (UC Berkeley, UC San Francisco, and Stanford University, among others).









LinkedIn Membership

Our LinkedIn Group has also seen continued growth over the last year and is becoming an increasingly important component in our mission of promoting public awareness of the life science industry, encouraging business opportunity and exchange, and serving as a bridge for the life science industry throughout the Asia Pacific.





CABS Membership Benefits

- Participate in activities and events organized by CABS and our partner organizations
- Significant discounts for CABS event registrations, including the BioPacific Conference
- Complimentary participation many CABS programs including the highly popular CABS Career Advisory Network (CAN) program
- Active engagement by volunteering to help organiz organize our events
- Leadership opportunity by joining our Executive Council

Membership Options	Price
Regular Membership for 1 year	$30
Regular Membership for 2 year	$50
Life Time Membership	$300

Join CABS today at: *http://www.cabsweb.org/members/*

CABS Sponsorship Benefits

You can sponsor CABS activities, including BioPacific Conference, either as a major sponsor or as a vendor show participant at an event of interest. Please contact fundraising team via e-mail: fundraising@cabsweb.org.

Benefits of Being CABS Sponsors

- Access to large pool of high profile members in various fields of life sciences
- Gain exposure through promotion at many CABS events, various publication materials, and internet
- Establish close relations and boost business opportunities with hundreds of other pharmaceutical and biotechnology companies in both US and Pacific Rim Countries
- Receive US tax benefits for your financial contribution

BioPacific Conference Sponsors Benefits
(Different level sponsors will receive different benefits, please contact fundraising@cabsweb.org for details)

- Panel Discussion at Annual Conference (please Inquire)
- Advertisement in Conference Brochure
- Logo in Conference Brochure, CABS Website, Conference Website and Promotional Materials
- Free Passes
- Free Membership
- Exhibition Booth
- Promotional Opportunities in other CABS Events
- Job Postings

CABS
Chinese-American Bio/Pharmaceutical Society
北美华人生物医药协会

2019 BioPacific Conference
21st Annual Conference of CABS
8:00AM - 7:00PM, June 22, 2019
San Mateo Marriott, 1770 South Amphlett Blvd.
San Mateo, CA 94402